» Articles » PMID: 22843568

Characterization of Human-induced Pluripotent Stem Cell-derived Cardiomyocytes: Bioenergetics and Utilization in Safety Screening

Overview
Journal Toxicol Sci
Specialty Toxicology
Date 2012 Jul 31
PMID 22843568
Citations 90
Authors
Affiliations
Soon will be listed here.
Abstract

Cardiotoxicity remains the number one reason for drug withdrawal from the market, and Food and Drug Administration issued black box warnings, thus demonstrating the need for more predictive preclinical safety screening, especially early in the drug discovery process when much chemical substrate is available. Whereas human-ether-a-go-go related gene screening has become routine to mitigate proarrhythmic risk, the development of in vitro assays predicting additional on- and off-target biochemical toxicities will benefit from cellular models exhibiting true cardiomyocyte characteristics such as native tissue-like mitochondrial activity. Human stem cell-derived tissue cells may provide such a model. This hypothesis was tested using a combination of flux analysis, gene and protein expression, and toxicity-profiling techniques to characterize mitochondrial function in induced pluripotent stem cell (iPSC) derived human cardiomyocytes in the presence of differing carbon sources over extended periods in cell culture. Functional analyses demonstrate that iPSC-derived cardiomyocytes are (1) capable of utilizing anaerobic or aerobic respiration depending upon the available carbon substrate and (2) bioenergetically closest to adult heart tissue cells when cultured in galactose or galactose supplemented with fatty acids. We utilized this model to test a variety of kinase inhibitors with known clinical cardiac liabilities for their potential toxicity toward these cells. We found that the kinase inhibitors showed a dose-dependent toxicity to iPSC cardiomyocytes grown in galactose and that oxygen consumption rates were significantly more affected than adenosine triphosphate production. Sorafenib was found to have the most effect, followed by sunitinib, dasatinib, imatinib, lapatinib, and nioltinib.

Citing Articles

Advancements in understanding cardiotoxicity of EGFR- TKIs in non-small cell lung cancer treatment and beyond.

Li X, Lin Y, Lin S, Huang J, Ruan Z Front Pharmacol. 2024; 15:1404692.

PMID: 39211774 PMC: 11357958. DOI: 10.3389/fphar.2024.1404692.


Hypothermic and cryogenic preservation of cardiac tissue-engineered constructs.

Janssen J, Chirico N, Ainsworth M, Cedillo-Servin G, Viola M, Dokter I Biomater Sci. 2024; 12(15):3866-3881.

PMID: 38910521 PMC: 11265564. DOI: 10.1039/d3bm01908j.


Independent compartmentalization of functional, metabolic, and transcriptional maturation of hiPSC-derived cardiomyocytes.

Fetterman K, Blancard M, Lyra-Leite D, Vanoye C, Fonoudi H, Jouni M Cell Rep. 2024; 43(5):114160.

PMID: 38678564 PMC: 11247623. DOI: 10.1016/j.celrep.2024.114160.


Challenging the status quo: a framework for mechanistic and human-relevant cardiovascular safety screening.

Berridge B, Pierson J, Pettit S, Stockbridge N Front Toxicol. 2024; 6:1352783.

PMID: 38590785 PMC: 10999590. DOI: 10.3389/ftox.2024.1352783.


iPSC-cardiomyocytes in the preclinical prediction of candidate pharmaceutical toxicity.

Lee T, Coles J, Maynes J Front Pharmacol. 2024; 15:1308217.

PMID: 38482053 PMC: 10933010. DOI: 10.3389/fphar.2024.1308217.